用乌斯特基努马布治疗的棕叶植物性牛皮炎儿童的乳酸性塑性支气管炎
Emily M Meara1, Dorothy L Curran2, Karen Wiss1,3
1Department of Dermatology, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Pediatric dermatology
|August 20, 2025
概括
治疗牛皮的乌斯特基努马布在儿童中可能很少引起乙酸性塑性支气管炎. 这份病例报告详细介绍了一个儿童在停止服用乌斯提努马布后, 通过使用类固醇和梅波利祖马布成功康复.
科学领域:
- 儿童肺病学
- 皮肤病学
- 免疫学
背景情况:
- 乌斯特基努马布是一种用于治疗牛皮的互白素-12/ 23抑制剂.
- 在成年人中,不良呼吸道事件,包括乙性肺炎和塑性支气管炎,很少与乌斯特基努马布相关.
- 在治疗皮肤病症的儿科患者中,这些病症的发生情况未得到充分证实.
相关概念视频
Asthma: Pathogenesis and Management
581
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
581
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
453
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
453
Asthma-II: Pathophysiology and Classification
2.8K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.8K
Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
Antiasthma Drugs: Leukotriene Modifiers
463
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
463
COPD: Management Using Bronchodilators and Corticosteroids
307
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
307


